UM
Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
Zheng, Wei; Cai, Dong-Bin; Yang, Xin-Hu; Ungvari, Gabor S.; Ng, Chee H.; Mueller, Norbert; Ning, Yu-Ping; Xiang, Yu-Tao
2017-09
Source PublicationJOURNAL OF PSYCHIATRIC RESEARCH
ISSN0022-3956
Volume92Pages:139-146
AbstractNeuroinflammation has been implicated in the neurobiological pathways of schizophrenia. This meta analysis evaluated the efficacy and tolerability of adjunctive celecoxib as a noncompetitive anti inflammation drug in treating schizophrenia. Data were searched, extracted, checked and entered into the RevMan (version 5.3) software by two independent investigators. Standardized/weighted mean differences (SMDs/WMDs), risk ratio (RR) and their 95% confidence intervals (Cls) were calculated, as appropriate. Included were 8 randomized controlled trials (RCTs) with a total of 626 patients with schizophrenia including 316 (50.5%) treated on celecoxib (400 mg/day) and 310 (49.5%) on placebo over 8.3 2.3 weeks of treatment. Adjunctive celecoxib outperformed placebo with respect to total psychopathology [3 RCTs, n = 180; SMD: -0.47; 95%Cl: -0.81, -0.14; P = 0.005; I-2 = 18%; 'moderate quality'], symptoms positive [3 RCTs, n = 180; SMD: -0.50; 95%CI: -0.79, 0.20; P = 0.001; I-2 = 0%; 'moderate quality], negative symptoms [3 RCTs, n = 180; SMD: 0.32; 95% CI: 0.66, 0.02; P = 0.06; = 22%; 'moderate quality'], and general psychopathology scores [3 RCTs, n = 180; SMD: 0.35; 95% CI: 0.65, 0.06; P = 0.02; I-2 = 0%; 'moderate quality'] in first-episode, but not chronic patients. Additionally, superiority of celecoxib for the Positive and Negative Syndrome Scale (PANSS) total scores was moderated by higher PANSS positive scores and lower PANSS negative scores at baseline. All-cause discontinuation [RR: 1.02; (95%Cl: 0.56,1.86); P = 0.94; I-2 = 0%] and adverse drug reactions were similar between the two groups. Adjunctive celecoxib appears to be an efficacious and safe treatment in improving psychotic symptoms, particularly in first-episode schizophrenia. (C) 2017 Elsevier Ltd. All rights reserved.
KeywordCelecoxib Schizophrenia Negative symptom First episode Meta-analysis
DOI10.1016/j.jpsychires.2017.04.004
URLView the original
Indexed BySCI ; SSCI
Language英语
WOS Research AreaPsychiatry
WOS SubjectPsychiatry
WOS IDWOS:000404701100018
PublisherPERGAMON-ELSEVIER SCIENCE LTD
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:18   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
Recommended Citation
GB/T 7714
Zheng, Wei,Cai, Dong-Bin,Yang, Xin-Hu,et al. Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials[J]. JOURNAL OF PSYCHIATRIC RESEARCH,2017,92:139-146.
APA Zheng, Wei.,Cai, Dong-Bin.,Yang, Xin-Hu.,Ungvari, Gabor S..,Ng, Chee H..,...&Xiang, Yu-Tao.(2017).Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.JOURNAL OF PSYCHIATRIC RESEARCH,92,139-146.
MLA Zheng, Wei,et al."Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials".JOURNAL OF PSYCHIATRIC RESEARCH 92(2017):139-146.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.